MONTREAL, Sept. 10, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., is pleased to announce that Octasa® 800 mg and Octasa® 1600 mg now have public coverage in most Canadian provinces. As of ...
Tillotts, part of the Japanese Zeria Group, is offering Octasa 1600 mg (mesalazine) delayed-release tablets as first-line treatment for moderately active ulcerative colitis in Canada. “Tillotts has a ...
We recognise that spending time reading about the dry and factual world of pharmaceutical products and strange diseases is perhaps not the norm for an IPA Effectiveness Awards submission document but ...
As of September 2024, Octasa ® has been added to the following provincial formularies as general benefit: Ontario 1, Alberta 2, New Brunswick 3, Newfoundland and Labrador 4, Nova Scotia 5, ...
The MarketWatch News Department was not involved in the creation of this content. MONTREAL, Sept. 10, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., is pleased to announce that Octasa(R) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results